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A B S T R A C T
Amylin is a peptide hormone that is mainly known to be produced by pancreatic β-cells in response to a meal but
amylin is also produced by brain cells in discrete brain areas albeit in a lesser amount. Amylin receptor (AMY) is
composed of the calcitonin core-receptor (CTR) and one of the 3 receptor activity modifying protein (RAMP),
thus forming AMY1−3; RAMP enhances amylin binding properties to the CTR. However, amylin receptor
agonist such as salmon calcitonin is able to bind CTR alone. Peripheral amylin’s main binding site is located in
the area postrema (AP) which then propagate the signal to the nucleus of the solitary tract and lateral para-
brachial nucleus (LPBN) and it is then transmitted to the forebrain areas such as central amygdala and bed
nucleus of the stria terminalis. Amylin’s activation of these different brain areas mediates eating and other
metabolic pathways controlling energy expenditure and glucose homeostasis. Peripheral amylin can also bind in
the arcuate nucleus of the hypothalamus where it acts independently of the AP to activate POMC and NPY
neurons. Amylin activation of NPY neurons has been shown to be transmitted to LPBN neurons to act on eating
while amylin POMC signaling affects energy expenditure and locomotor activity. While a large amount of ex-
periments have already been conducted, future studies will have to further investigate how amylin is taken up by
forebrain areas and deepen our understanding of amylin action on peripheral metabolism.
Amylin was discovered more than 30 years ago in type 2 diabetic
patients and diabetic cats and was shown to aggregate in pancreatic
islets [1]. Amylin is best known to be co-secreted with insulin by
pancreatic β-cells in response to a meal and has been first identified as a
satiating peptide hormone controlling food intake by decreasing meal
size ([2] for review see [3–5]). Amylin belongs to the calcitonin peptide
family which includes adrenomedullin, calcitonin and calcitonin-gene-
related peptide (CGRP). The amylin peptide sequence is very well
conserved across species [6] and the difference in amino acid sequence
between humans and cats versus rodents prevents rodents amylin to
aggregate [7]. Thus most of the amylin analogues such as pramlintide
and future amylin receptor agonists in clinical development present an
amino-acid sequence close to the rodent amylin. In addition to its an-
orectic property, amylin acts on multiple forebrain and hindbrain brain
pathways to control different aspects of food intake, energy metabolism
and reward. A specific chapter will explore the fact that amylin is also
produced in the brain; whether and how it is secreted and regulated is
still under investigation [8,9]. Last, amylin functions on gastric emp-
tying and glucose control will be examined.
1. Amylin receptor and signaling
1.1. Amylin receptor subunits and binding
The amylin receptor (AMY) is composed of multi-subunits of the
calcitonin receptor (CTR) which comprise the isoform 1A and 1B and
the receptor activity modifying protein (RAMP) 1, 2 or 3 leading to the
formation of AMY1, AMY2 and AMY3 [10].
CTR belongs to the family of the cell surface G coupled protein re-
ceptors. CTR presents different allosteric binding sites allowing the
receptor to modulate its affinity to different ligands [10]. CTR receptors
are located throughout the body. CTR is present in osteoclasts where it
is the target for calcitonin but also in osteocytes, kidneys, testes, pla-
centa, lungs and the brain. In the adult rodent brain, CTR1A and 1B
have been localized using immunohistochemistry [7,11,12] and in situ
hybridization [13,14]. CTR1A and 1B differ by the absence (1A) or the
presence (1B) of a 16 amino acid insert in the first intracellular loop
[15] leading to a poorer internalization and altered coupling to G-
coupled proteins of CTR1B [16]. In the brain, CTR expression is the
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most abundant in the nucleus accumbens (NAc), ventral tegmental area
(VTA) [17], arcuate nucleus (ARC), ventromedial hypothalamus (VMN)
[14], lateral hypothalamus (LH), lateral substantia nigra, bed nucleus of
the stria terminalis (BNST), locus coeruleus, area postrema (AP) and
nucleus of the solitary tract (NTS) [12]. While most of these studies
have been performed on rat brain, it is possible that slight differences
might occur between rat and mouse brain [12,18].
At the protein level, RAMP location is more elusive due to the ab-
sence of specific antibodies. Nevertheless, mRNA expression of RAMP1
has been detected in the lungs, muscle and brain. RAMP2 mRNA ex-
pression was also detected in lungs, heart, skeletal muscle, endothelial
tissue and brain. RAMP3 is mostly expressed in the brain and to a lesser
amount in peripheral tissues such as the gut, lung, heart and kidney
[19]. More specifically, in the brain, using in situ hybridization, RAMP1
is localized in the brainstem, AP, NAc, cortex, hippocampus, caudate
putamen, olfactory tubercles, subcomissural organ [20]. RAMP2 mRNA
expression is abundant in the hypothalamus [19] and is also expressed
but at a lower level in olfactory bulb, hippocampus, choroid plexus of
the 3rd, 4th and lateral ventricles and blood vessels throughout the brain
[20,21]. RAMP3 is the most abundant in the dorsal thalamus [19],
lateral geniculate, and lower amounts are detected in the subfornical
organ (SFO) and AP. In the medio-basal hypothalamus, all three RAMPs
have been detected in microglial, astrocyte and neuronal primary cell
culture of male rats [22]. While the study of RAMP1 or RAMP3 is
possible using global KO mouse models [23–25]. RAMP2 KO in mice is
lethal due to the presence of RAMP2 in endothelial tissues and lack of
RAMP2 during development leads to embryonic lethality [26].
AMY formation results from the co-localization of CTR and RAMP
within the same cell. RAMP heterodimerization with CTR increases the
accessibility of the CTR extracellular binding domain to enhance the
binding of amylin [27]. Thus, at the cell level in rat, RAMP1, 2 and 3
and CTR1A have all been detected in the same cell in the AP with a
preference for CTR being co-localized with RAMP3 [28]. Our recently
published data also co-localized RAMP3 or RAMP1 mRNA and CTR
peptide in the ARC and NTS [18]. It is however unknown if multiple
AMY isoforms are present simultaneously in one cell and if these AMY
isoforms can be specifically generated according to metabolic demands.
125I amylin binding experiments on brain sections [14,29,30] or in vivo
fluorescent amylin uptake [31] have uncovered amylin site-specific
areas. The most prominent areas are located in the medial preoptic area
(MPO), ARC, VMN, dorsomedial hypothalamic nucleus (DMN), NAc
and in the hindbrain with the AP, caudal NTS and dorsal raphe
[14,29,30]. Whole brain 3D imaging showed that fluorescent salmon
calcitonin (sCT; amylin receptor agonist) and rat amylin distributed
mainly into the ARC, AP and organum vasculosum of the lamina ter-
minalis (OVLT) of the mouse brain. Surprisingly, no sCT signal was
observed in NTS [31]. Using monkey brain sections, further experi-
ments compared the binding of 125I amylin and 125I sCT. Interestingly
[32,33] some areas with strong sCT binding did not bind amylin. Si-
milarly, fluorescent amylin uptake showed signal using whole-brain
imaging in the median eminence (ME) while fluorescent sCT did not
[31]. These data are of importance given the use of sCT as an amylin
receptor agonist which could lead to the activation of pathways that are
not activated by native amylin [34]. One caveat using 125I ligand
binding experiment is that it only indicates whether the receptor is
present but cannot indicate whether the native peptide can bind and
reach these areas in a physiological setting. Thus, the uptake of fluor-
escent peptide and the use of whole-brain imaging may be a better
physiological indicator of how a native peptide acts in the brain.
1.2. Receptor ligand affinity
Together CTR and RAMP can bind multiple ligands with different
affinity [34,35]. CTR alone presents the greatest affinity for calcitonin
and its receptor agonist sCT. AMY1 binds sCT, amylin and CGRP with
the same affinity. Indeed, AMY1 is considered as the second CGRP
receptor [33,36]. Since CGRP is a neuropeptide widely distributed in
the brain and since CGRP plays an important role in controlling energy
metabolism [33,36–39], it may act as a confounding factor when as-
sessing amylin’s effects particularly in the LPBN or ARC where both
amylin and CGRP have binding sites [13,14,40]. AMY2 and AMY3
preferentially bind amylin and sCT compared to CGRP. The multiple
allosteric binding sites present on AMY allow each ligand to pre-
ferentially bind to specific receptor conformations in order to activate
downstream signaling pathways [35].
In addition to CTR, RAMP can bind another receptor, the calcitonin
like receptor (CLR). CLR and RAMP1 form the primary CGRP receptor
[10]. CLR-RAMP2 forms the adrenomedullin 1 receptor (AM1) and
CLR-RAMP3 forms the AM2. AM1 preferentially binds adrenomedullin
while AM2 binds adrenomedullin and adrenomedullin 2/intermedin
with the same affinity. Thus, whole-body RAMP KO animal models
assess diverse metabolic functions and not just amylin related signaling
[24].
1.3. Amylin intracellular signaling
CTR is a GPCR. Thus, once the ligand is bound to the AMY, it ac-
tivates several intracellular signaling pathways [34]. Amylin receptor
signaling has been mostly studied using cell culture and transfected
AMY receptors where amylin has been shown to activate G-coupled
pathways and the production of cAMP [41]. On the other hand, it has
also been shown in rats that amylin increases intracellular cGMP, and
the local administration of a cGMP analog in the AP produced similar
effects on eating as amylin [42,43]. In vivo, exogenous amylin activates
ERK signaling [44] and induces the phosphorylation of ERK1/2 in the
AP and ARC [24,44]. Under specific conditions, inhibition of ERK sig-
naling pathway in the AP is able to reduce ERK phosphorylation and
eating in rats [44]. The absence of RAMP1 and 3 reduces amylin-in-
duced ERK phosphorylation in the ARC [22].
2. Amylin brain uptake
In 1998, Banks et al. performed a study assessing amylin’s ability to
cross the blood brain barrier by measuring the regional distribution
within the brain of radioactively labelled amylin and insulin [45].
Using multiple-time regression analysis, the unidirectional influx con-
stant (Ki) and volume distribution (Vi) were evaluated in pons-medulla,
cerebellum, midbrain, hypothalamus, thalamus, hippocampus,
striatum, frontal cortex, parietal cortex, and occipital cortex [46]. Pons-
medulla had the highest levels and whereas the thalamus presented the
slowest amylin uptake. The parietal cortex, occipital cortex, and the
hypothalamus had uptake values that varied less than 10 % from that of
the whole brain. Given the small variation between different brain
areas, this study may suggest that amylin is diffused or transported into
the brain but does not inform about the physiological or the pharma-
cological relevance of this event since amylin uptake takes place in
brain areas where amylin receptor expression has not been shown [32]
such as the parietal and occipital cortex.
More recently, a study compared amylin concentrations in the cer-
ebrospinal fluid (CSF) between patients suffering from Alzheimer’s
disease (AD) and healthy control subjects [47]. Amylin concentrations
in the CSF were not correlated to AD, however CSF amylin increased
along with plasma amylin, suggesting that amylin in the CSF mostly
originates from peripheral and not central amylin. It is thus important
to investigate whether amylin passively diffuses into CSF or is actively
transported. This can be tested by increasing peripheral amylin con-
centration and measuring CSF amylin levels. If CSF amylin levels
stopped reflecting peripheral amylin, this would indicate saturation and
thus the existence of a transporter.
The most recent study about amylin brain uptake by Zakariassen
et al. described amylin and sCT brain distribution using whole brain 3D
imaging and confocal microscopy following the peripheral injection of
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fluorescently labelled peptides in mice. In order to investigate binding
and internalization of fluorescently labelled amylin and sCT in ARC to
NPY and/or POMC neurons, hrGFP-NPY and POMC-
Cre:ERT2:tdTomato mice were used. NPY neurons seemed to be the
preferential target for sCT since no binding was observed on POMC
neurons. Whole brain imaging showed amylin and sCT distribution in
AP, OVLT and ARC [31]. Moreover, amylin and sCT signals were ob-
served in brain tissues and in the choroid plexus indicating presence of
fluorescently labelled peptide in the blood vessels. Interestingly, unlike
sCT, an amylin signal was observed in ME. This difference in brain
distribution could be suggestive of some kind of transport mechanism
behind amylin uptake. Considering the location of amylin uptake in the
ME and in the medio-basal ARC, it is suggestive of tanycytic involve-
ment in the transport similar to what has been shown with leptin [48].
The discovery of an amylin-specific transporter in brain areas with a
functional blood brain barrier may suggest a physiological function for
amylin uptake and that peripheral amylin can activate signaling path-
ways in different brain areas independently of the AP. On the other
hand, it is also known that peripheral peptides can passively diffuse in
the brain through periventricular fenestrated capillaries and they are
quickly destroyed by peptidases present in the inter-neuronal space
[49]. This may be the case with amylin uptake, considering the ne-
cessity of extremely high dose and very short time window of its de-
tection [31]. The limited ability of peripheral amylin to reach brain
regions where amylin receptors are located [32], may perhaps have
been evolutionary compensated by central amylin production. More
experiments are however needed to fully understand and clarify amylin
brain uptake and identify how amylin can cross into the ME.
3. Amylin brain production
To this day, only a few studies have actively investigated amylin
production in the brain even though first reports about the possibility of
central amylin synthesis had already been published years ago [50–52].
The first paper that investigated in detail this issue, was published in
2009 by Dobolyi and they showed a 24-fold increase in amylin mRNA
expression in rostral MPO of lactating rat dams compared to pup de-
prived dams and nulliparous females. Interestingly, no amylin mRNA
expression was detected in male rats [9]. The difference in amylin ex-
pression between lactating rat dams and pup-deprived lactating rat
dams may be indicative of oxytocin playing major role in inducing
amylin expression since oxytocin is released in response to suckling
[53]. Overall, the elevation of amylin expression in the MPO, the major
brain area mediating maternal behaviors [54,55], is suggestive of
central amylin’s involvement in maternal adaptations. However, de-
tailed studies will be necessary to test whether MPO amylin regulates
metabolic or behavioral maternal adaptations.
The second study describing amylin expression in the brain was
performed more recently by Li et al. in 2015 [8], which primarily in-
vestigated the role of prodynorphin (Pdyn) neurons in obesity. Using
immunohistochemistry, they showed that Pdyn was co-expressed with
amylin in multiple hypothalamic nuclei including cell bodies in MPO,
ARC, LHA and fibers in paraventricular nucleus of the hypothamus
(PVN), dorsal medial hypothalamus (DMH) and in the preoptic area.
Amylin positive cells were mostly co-expressed with Pdyn in the LH and
MPO and with orexin in the LH. Given the shape of the amylin positive
cells in immunohistochemical staining and the fact that these cells were
co-expressed with markers mostly found in neurons, amylin was sug-
gested to be expressed in neuronal cells but further immunostainings
are required to confirm the exact cell type of amylin positive cells.
While in the study by Dobolyi, amylin mRNA expression was detected
in female rats only, Li et al. observed a sexual dimorphism in mice with
total hypothalamic amylin mRNA expression being significantly higher
in WT female mice compared to WT male mice. However, this di-
morphism was reversed in animals exposed to a 60 % HFD, suggesting
that HFD increases hypothalamic amylin production in males and
decreases it in females [8].
Interestingly, amylin expression was reduced in the hypothalamus
of leptin-deficient ob/ob female and male mice and it was restored by 3-
month treatment with exogenous leptin [8]. Neurons in the LH were
also sensitive to amylin and leptin when assessed using patch-clamping
[8]. Moreover, ob/ob mice that re-express leptin after tetracycline
treatment [56] expressed significantly higher levels of hypothalamic
amylin in both male and female mice. Since amylin has been shown to
enhance leptin signaling in the medio-basal hypothalamus [57–59],
these findings may lead to a conclusion that brain leptin signaling may
contribute to the regulation of brain amylin expression; however, the
physiological relevance of these phenomena remains to be investigated.
To investigate the role of central amylin on food intake, Li et al.
infused the amylin antagonist AC187 into the lateral ventricle prior to
an intraperitoneal (i.p.) leptin injection. They observed that leptin’s
anorexic effect in the first 2 h was abolished in groups treated with
AC187. Although this result confirms previous studies about peripheral
amylin’s synergistic and additive effect on leptin [57,60,61], it is too
early to conclude on the exact underlying mechanisms.
Together these studies confirm the secretion of amylin by discrete
brain areas and its regulation seems to be controlled by sex, leptin and
diet but whether brain-secreted amylin plays an important role com-
pared to peripheral amylin remains to be assessed.
4. Amylin brain signaling and peripheral action
4.1. Hindbrain pathways: amylin regulation of food intake
Building up on a large number of studies, peripheral amylin has
been shown to activate neurons in the AP which then propagate its
signal to the lateral parabrachial nucleus (LPBN) and to subsequent
downstream nuclei such as the central nucleus of the amygdala (CeA)
and the bed nucleus of the stria terminalis (BNST).
4.2. The area postrema
The AP in the hindbrain, lies on the dorsal surface of the medulla
oblongata at the caudal end of the fourth ventricle [62]. Lacking a
blood-brain barrier, the blood hormones/peptides can move through
the porous BBB in the AP and bind to neurons [63]. Furthermore, the
AP is surrounded laterally and innervated by the nucleus of the solitary
tract (NTS) [64], which comprises the primary sensory areas for both
gustatory (facial, glossopharyngeal, and vagus nerves) and visceral
(vagus nerve) afferents [65–67]. The vagus nerve also innervates the AP
directly [68,69]. Thus, the AP is in a likely position to integrate che-
mical signals from the blood stream and receives neural signals from
gustatory and visceral receptors to modulate intake and control body
weight [70]. A large number of studies performed in different labora-
tories indicate that the AP plays a primary role in mediating effects of
peripheral amylin (for review see [34]). Amylin directly activates AP
neurons via the activation of AMYs, which are highly expressed in the
AP [29], determining an increase of the marker of neural activation c-
Fos. Indirect activation of the AP via afferent signaling (vagal or non-
vagal) does not seem to be involved in amylin's effects on eating
[71–77] (see section 6 for a further discussion on the role of the vagus
in amylin's effects). Electrophysiological and immunohistochemical
studies supported a direct action of amylin on AP neurons
[42,44,78,79]. The best-studied amylin action is to reduce food-intake
[34] and the primary role of AP was confirmed by the fact that AP/NTS
lesions completely blocked amylin’s anorectic effect [71]. Furthermore,
local amylin administration into the AP recapitulates peripheral amy-
lin’s effect, whereas the amylin antagonist AC187 has the opposite ef-
fect [44]. One of the further actions of amylin is to reduce gastric
emptying (see section 6), and the AP also seems to be necessary for
amylin to mediate this function [73,80–82].
The phenotype of amylin and sCT activated neurons in the AP is
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mainly noradrenergic; following systemic amylin administration, half
of c-Fos positive neurons are co-localized with dopamine-β-hydroxylase
(DBH), the key enzyme in noradrenaline (NA) synthesis and marker of
noradrenergic neurons [83]. DBH-positive neurons in the AP seem to be
necessary for peripheral amylin to reduce eating [84]. Previous work of
our group showed that the selective ablation of the NA-containing
neurons with the immunotoxin anti-DBH-saporin (DSAP) in AP is suf-
ficient to abolish the hypophagic effect of amylin [84]. Further studies
are however needed to investigate the role of the NA system in other
reported amylin effects that are presumed to be mediated via the AP,
such as the inhibition of gastric emptying, pancreatic glucagon secre-
tion, the increase of energy expenditure and the modulation of CCK-
induced anorexia [84]. While more than approximately half of amylin
activated neurons are noradrenergic, further studies are needed to
characterize the neurochemical nature of the remaining non-nora-
drenergic amylin activated AP neurons and their possible function. A
recent electrophysiological study suggested that glutamatergic neuro-
transmission in the AP may mediate or rather modulate amylin's effect;
indeed, AMYs appear to be mainly located on presynaptic glutamatergic
terminals connecting to AP neurons, and amylin has been shown to
increase glutamate release and cause cell firing [85]. In addition, ve-
sicular glutamate transporters (VGLUT2) boutons were shown to be
apposed to amylin activated noradrenergic neurons in AP [83].
A large number of studies indicate that the AP has a key role in the
mediation of nausea/emesis [86–88]. Electrophysiological and im-
munohistochemical studies have reported that AP neurons respond to
emetic agents and the ablation of AP prevents vomiting in response to
emetic drugs [89]. However, such effects do not seem to be triggered by
amylin. Many studies have shown that systemic amylin and sCT, or 4th
ventricle amylin administration do not cause aversive or sickness-like
behaviors indicative of a nausea/emesis, thus suggesting that the an-
orectic effects of amylin are not mediated by malaise [90–92]. Con-
versely, high doses of sCT (150 ug/kg) which are approx. 10 times
higher than doses used routinely to study amylin’s effect on eating,
were recently shown to induce a conditioned taste avoidance (CTA)
response [93]; thus, further studies are needed to characterize if it is a
dose dependent effect. It is possible to define that emetic and amylin-
anorectic signals, while acting on the same brain area, use different
neural circuitry. Indeed, amylin and lithium chloride, an aversive sti-
muli, do no activate the same AP neurons and lithium chloride-induced
c-Fos positive neurons are negative for CTR [94] but whether this is also
true for NTS remains to be determined. These studies are crucial given
the development of dual AMY/CTR agonists by pharmaceuticals in-
dustries to combat obesity.
4.3. The lateral parabrachial nucleus
Amylin’s satiation effect is mainly mediated by the primary acti-
vation of neurons in the AP, which then signal other downstream nu-
clei, such as the LPBN [71,78,95]. The LPBN consists of a complex of
neurons in the dorsolateral pons and it plays an important role in
mediating a variety of visceral functions such as taste, respiration,
central cardiovascular control and sleep [96]. The parabrachial nucleus
in rodents [97] as well as primates [98] is a key relay for visceral sig-
nals from the caudal hindbrain to forebrain areas associated with ap-
petite control. LPBN receives axonal inputs from different brain areas,
such as the AP and NTS, and its neurons project to numerous forebrain
regions, including the CeA and BNST [99]. The LPBN has been de-
monstrated to be a crucial brain site mediating the anorectic effect of
amylin [37,95] because an ablation of the LPBN reduced amylin's an-
orectic effect and abolished the neural activation in CeA, reflected by
the lack of the c-Fos expression [95]. While the phenotype of amylin
activated neurons in AP has been shown to be mainly noradrenergic,
the LPBN-specific neuronal populations responsible for the mediation of
amylin’s effect remain unknown. Previous studies showed that a high
percentage of LPBN neurons express CGRP [100]. More recent studies
showed that CGRP neurons inhibit feeding when activated by satiation
signals such as cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1),
and that these neurons directly project to CeA [37]. More specifically,
the chemogenetic inhibition of CGRPLPBN neurons partially decreased
amylin’s ability to reduce food-intake and these neurons where co-lo-
calized with c-Fos after systemic amylin administration [37]. Interest-
ingly, these neurons are not just involved in mediating anorexia and
satiation, but also relay a wide variety of aversive signals (food poi-
soning, pain, foot shock, itch etc.) and taste memories [101]. However,
the exact neurotransmitter of CGRPLPBN neurons that mediates amylin's
effect remains unknown and is in need of more investigation. A recent
study proposed that part of sCT's anorectic effect is mediated by the
activation of non-CGRPLPBN neurons, through the direct activation of
the CTR neurons in the NTS [93]. Hence, more work is necessary to
define in detail the role of LPBN neuronal populations in the mediation
of amylin's effects.
Last, we can also hypothesize that amylin may activate AP and NTS
neurons in parallel, and that these neurons may in turn activate dif-
ferent neuronal populations of the LPBN. Indeed, a large proportion of
noradrenergic neurons from the AP are known to project to NTS [102]
but direct catecholaminergic projections from the AP to the LPBN have
also been shown to convey hormonal and enteroceptive signals from the
hindbrain to the forebrain [103]. The specific role of noradrenergic AP-
LPBN and AP-NTS-LPBN projections mediating amylin's effects needs to
be clarified.
4.4. The central amygdala
Retrograde labelling techniques showed that a large portion of
LPBN neurons innervate the CeA [104]. Neurons of the CeA are in-
volved in emotional processing, learning, memory as well as aversive
situations such as stress or fear and pain [105–107]. Less is known
about CeA’s role in the control of feeding behavior [108]. However, the
neuroanatomical location and the phenotype of amygdala neurons
suggest a potential contribution to feeding control. Reciprocal con-
nections between the amygdala and nearly all key energy balance
regulation nuclei exist and include projections to and from the hy-
pothalamus, NTS, ventral tegmental area (VTA), NAc and parabrachial
nucleus [109]. Moreover, amygdala neurons may directly sense gut
hormones, as receptors for ghrelin and glucagon-like peptide 1 (GLP-1)
have been identified on amygdala neurons [110,111]. Interestingly
AMY receptor components are expressed in CeA [29]. Thus, the
amygdala is in a key neuroanatomical position that allows the sampling
and the integration of inputs relevant to feeding and metabolic status
from both the internal and external milieus but whether peripheral
amylin can access this brain site has never been demonstrated. A recent
study showed that dopamine transmission in the amygdala controls
food intake and reward; food-intake is associated with increased do-
pamine turnover in the amygdala and activation of dopaminergic 2
receptors (D2) reduced food-intake [112].
As mentioned, the CeA may be involved in amylin's effect on eating
because systemic amylin administration induces neural activation in
CeA [78] and because the ablation of LPBN reduces amylin anorectic
effect and abolishes the neural activation in CeA [95]. Furthermore,
CGRPLPBN neurons directly project to CeA [39]. The lateral subdivision
of CeA contains a subpopulation of GABAergic neurons, the PKC-δ+
neurons, identified by the presence of protein kinase C-δ [113]. The
optogenetic activation of these neurons strongly suppresses food intake
[113]. PKC-δ+ neurons in mice are activated by CCK and LiCl, typical
anorexigenic signals, and the activity of these neurons is required for
the inhibition of feeding mediated by these signals. They receive pre-
synaptic inputs from anatomically distributed neurons activated by
different anorexigenic agents [113]. These data suggest that CeA PKC-δ
+ neurons constitute an important node that mediates the influence of
multiple anorexigenic signals but whether these neurons also receive
LPBN mediated- amylin signaling remains to be determined. Thus,
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further studies are needed to define the phenotype of amylin activated
neurons in CeA.
4.5. Ventral tegmental area: amylin’s role on the dopaminergic system and
reward
The VTA receives projections from the AP/NTS and projects to the
NAc [4,114]; recent findings have shown that the VTA and the meso-
limbic reward system seem to mediate amylin’s effect on energy bal-
ance [17,115]. It is thought that early satiation signals like amylin
impede food consumption by moderating reward system activity, re-
ducing its value [91,116,117]. Dopamine transmission may provide one
mechanism that bridges the sensations of hunger and satiation with
motivated behavior and there is evidence that peptides that govern food
intake can also exert their effects on feeding via dopaminergic me-
chanisms [118,119]. Peripheral sCT is able to reduce VTA-stimulated
release of dopamine in the NAc of rats, supporting the hypothesis that
the mesolimbic system is involved in amylin’s actions on food moti-
vation and intake [120]. Further, there is also evidence for the mod-
ulation of the dopaminergic system by amylinergic action in other sites
of brain such as the VTA and the lateral dorsal tegmental nucleus
(LDTg) [17,121–123]. The relationship between the effects mediated by
the VTA, LDTg and the AP is unclear at present. Given that LDTg is
reciprocally connected to both the AP/NTS and VTA, amylinergic ac-
tivation may involve a AP/NTS-LDTg-VTA pathway to modulate do-
pamine transmission. Currently the available data do not allow a clear
distinction between a direct activation of the pertinent receptors by
peripheral amylin or sCT or indirectly mediated effects [4,120].
Due to amylin’s well-established effects on satiation, a focus on the
modulation of the mesolimbic DA has centered around amylin’s effects
on feeding behavior. However, the findings that reward induced by
food and addictive drugs involve common mechanisms, raise the pos-
sibility that amylin could be involved in reward regulation [124]. In
this regard, sCT has been shown to attenuate the rewarding properties
of alcohol in rodents, and more specifically to decrease alcohol-induced
locomotor activity, NAc dopamine release, and conditioned place pre-
ference in mice, as well as alcohol intake in rats [125]. A better un-
derstanding of the effects of amylin activation on motivated behaviors
could inform future approaches targeting amylin signaling to treat both
behaviors and/or drug dependence.
5. Hypothalamic pathways
Amylin has long been promoted for anti-obesity treatment since
trial experiments with its synthetic analogue pramlintide in outbred,
diet-induced obese (DIO) rats resulted in sustained, fat-specific weight
loss [126]. In addition to the reduced food intake of treated animals,
pramlintide seemed to facilitate fat utilization and thus have beneficial
effects beyond caloric restriction in obese animals [127]. These effects
have been largely attributed to an improvement of leptin responsive-
ness, specifically in the ventromedial hypothalamus (VMH) [126]. In-
deed, selectively bred DIO rats show a reduction in 125I-amylin binding
in the VMH that leads to a reduction of leptin-induced pSTAT3. This
observation could be recapitulated by knocking down the amylin re-
ceptor in the VMH of DR rats, which resulted in reduced leptin sig-
naling, increased adiposity, hyperleptinemia and hyperinsulinemia in-
dependent of food intake [14]. Amylin-deficient mice show a reduction
of leptin receptor mRNA expression in the VMH and ARC, which results
in reduced pSTAT3 and an attenuation of leptin-induced weight re-
duction [59]. The exact mechanism of amylin/leptin-interaction is still
poorly understood but interestingly, hypothalamic microglia seem to
produce IL-6 in response to amylin and possibly play an important role
in increasing the ARC/VMH leptin response in both mice and rats
through indirect modulation with cytokines [57]. Gene expression data
from this study also showed that 5 days of systemic amylin treatment
upregulates neuropeptide Y (NPY) and agouti-related protein (AgRP) in
the ARC [57], while earlier studies with pramlintide showed increased
POMC expression in rats [127]. This led us to the question: what effects
occur from direct and leptin-independent amylin signaling onto these
specialized neuronal populations in the ARC?
5.1. POMC neurons
Pro-opiomelanocortin (POMC) neurons are first order neurons in
the hypothalamic control of body weight and reside mainly in the ARC
[128]. Early observations of rat brains after chronic pramlintide treat-
ment revealed an increase in POMC expression, but the predominant
effects of amylin analogues on food intake are mediated by the AP and
are not altered in mice that have inhibited melanocortin receptor sig-
naling [127,129]. In the AP, activation of the amylin receptor on
neurons leads to phosphorylation of extracellular-signal regulated ki-
nase 1/2 (pERK), and blocking this intracellular pathway attenuates the
inhibitory effect of amylin on food intake [44]. The same pathway
seems to be activated when amylin acts on hypothalamic POMC neu-
rons [22], where amylin was first hypothesized to converge with leptin
signaling. CTR knockout studies in POMC neurons have shown that
under physiological conditions, this pathway mainly mediates a ther-
mogenic response, possibly promoting energy expenditure through ac-
tivation of brown adipose tissue [18]. However, the effect of en-
dogenous amylin on POMC neurons was no longer observable in 45 %
HFD-fed knockout mice [18]. Additionally, mice that lack endogenous
amylin also don’t gain excess weight on HFD compared to wildtype
[59]. Thus, the lack of endogenous amylin signaling in the ARC does
not seem to worsen obesity under HFD conditions. Nevertheless, obese
animals do not develop amylin resistance, since various animal models
of obesity still respond well to pharmacological doses of amylin
[59,130,131].
5.2. NPY neurons
In the classic model of hypothalamic body weight control, neuro-
peptide Y (NPY) neurons play the orexigenic counterpart to POMC
neurons in the ARC [132,133]. While amylin can counteract pharma-
cological application of NPY and attenuate the orexigenic effect of NPY
[134], the endogenous expression of NPY is sometimes unchanged or
upregulated after amylin or pramlintide treatment [57,127,135]. When
pERK expression in the hypothalamus after amylin injection was as-
sessed, the increase in ERK phosphorylation was predominantly de-
tected in POMC neurons and not NPY neurons in mice and rats [22].
However, tracking of fluorescently labeled sCT, an agonist for AMY and
CTR, showed that NPY neurons and not POMC neurons are able to in-
ternalize this compound [31]. While NPY neurons express the necessary
components of the amylin receptor, it is still unclear what the direct
effect amylin on NPY neurons is, but one could hypothesize that it is of
inhibitory nature and therefore overlooked in studies assessing neu-
ronal activation. However, multiple factors are necessary to reverse the
fasting-induced activation of ARC neurons, meaning that these first-
order neurons already integrate several peripheral signals and en-
dogenous amylin alone may not be sufficient to block NPY-driven
feeding behavior [134].
5.3. Projections to second order neurons
Studies with unconditional amylin knockout mice and RAMP1/3-
knockout mice revealed that a lack of amylin or amylin signaling during
development results in a decrease of α-MSH fibers that project from the
ARC to the PVN. Parallel projections of NPY neurons with AgRP-con-
taining fibers are also reduced in RAMP1/3 KO mice, but increased in
the amylin KO [22] which may suggest a different role between other
AMY1/3 ligands and amylin. Generally, the presence of amylin seems
to promote the outgrowth of pathways to second order neurons which it
also activates under physiological conditions, e.g. the release of α-MSH
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to melanocortin-4 receptors (MC4R) [22,136]. Conversely, tamoxifen-
induced knockout of CTR in POMC neurons of weaned mice did not
affect the fiber density of α-MSH in the PVN [18]. These developmental
effects could be important since they might change how the brain reacts
to feeding-related signals later in life.
5.4. Do ARC and AP pathways join in LPBN?
Neurons located in the AP and ARC play both an important role in
mediating amylin’s anorectic effect and both nuclei project directly to
the LPBN. Surgical AP removal is sufficient to decrease peripheral
amylin’s and sCT’s hypophagic effect [96]. Conversely, systemic amylin
administration activates ERK signaling in POMC neurons of the ARC
through an AP independent pathway [22] and can suppress Agouti
Related Peptide AgRPARC neurons activity [137]. Indeed, AgRPARC sti-
mulation decreased the hyphophagic effect of exogenously applied
amylin and reduced c-Fos expression in CGRPLPBN neurons [138].
Therefore, given the fact that the amylin receptor agonist, sCT, binds to
ARCNPYneurons [31], it is possible that amylin can also activate LPBN
neurons by directly modulating ARC neurons via an AP-independent
neuronal circuit.
Food intake is regulated by AgRP and POMC ARC neurons with
AgRP neurons acting in opposition to POMC neurons. Indeed, the
chemogenetic inhibition of AgRP neurons significantly decreases
feeding [139] and genetic ablation of AgRP neurons causes severe
starvation [140]. In contrast, stimulation of AgRP neurons determines
an increase in food intake [141,142]. These neurons exert functions by
primarily via GABAergic signaling onto POMC neurons
[38,132,143,144] and also inhibit brain circuits that actively suppress
appetite, thus increasing feeding. Indeed, CGRPLPBN neurons increased
their activity following AgRP neuron ablation [38,143]. Further studies
are needed to investigate the specific role of ARC signaling in the
modulation of LPBN neural activity following amylin administration.
6. Mediation of gastric emptying and glucose control by systemic
amylin
While the previous chapters concentrated on the effect of amylin on
different brain nuclei, this last section will summarize findings on the
peripheral effect of amylin through vagal efferent fibers as well as its
role in regulating glucose secretion.
6.1. Amylin action on gastric emptying
Physiological concentrations of amylin have been shown to inhibit
liver gluconeogenesis, food intake, and gastric emptying in people
[145]. Many studies from our own laboratory and others have de-
monstrated that amylin activates AP neurons to perform its anorectic
action; this activation seems to be direct and vagal or non-vagal affer-
ents are not involved in mediating these effects [71,74–77,146].
Indeed, in rats, AMY and CTR agonists have been shown to decrease
gastric emptying which contributes to their effect to decrease eating
[73,147–149]. To assess the mechanisms of amylin on gastric emptying,
a subdiaphragmatic vagal deafferentation procedure (SDA) was per-
formed in rats. This procedure includes the unilateral severing of af-
ferent fibers of the vagus where they enter the brain stem while a
subdiaphragmatic vagotomy is performed on the contralateral side.
Thus, even though amylin slowed gastric emptying in sham-operated
Fig. 1. Schematic overview of signaling pathways controlled by peripheral and central amylin. (Left) Peripheral amylin is secreted by pancreatic β-cells in response
to nutrient intake. Amylin activates area postrema (AP)/nucleus of the solitary tract (NTS) neurons. Activation signal is then transmitted to downstream nuclei:
activation of neurons of the lateral parabrachial nucleus (LPBN) decreases food intake while the activation of neurons of the ventral tegmental area (VTA) and the
dopamine system mediates amylin’s rewarding properties. Peripheral amylin can also bind to arcuate (ARC) neurons to decrease food intake and to increase energy
expenditure. (Right) Amylin can be centrally produced by neurons of the medial preoptic nucleus (MPO), medial preoptic area (MPA) and multiple nuclei of the
hypothalamus. Central amylin production is enhanced in lactating dams and is stimulated by leptin. Nevertheless, the physiological function of central amylin
remains to be investigated.
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rats similarly to CCK, SDA did not attenuate gastric emptying in amylin-
treated rats contrary to CKK-injected rats [81]. Furthermore, total
subdiaphramagtic vagotomy [150] or lesion of the AP were able to
block amylin-mediated gastric emptying [151]. These results indicate
that amylin does not inhibit gastric emptying through vagal afferent
[81] but rather through the AP and vagal efferent fibers. Furthermore,
whole brain imaging revealed DMX fluorescent sCT binding [31] which
may imply that amylin or amylin receptor agonist might also mediate
gastric emptying by activating neurons of the DMX in addition to the
AP.
Amylin receptors are also expressed in the stomach of humans and
rats [152,153] but whether amylin is able to act on stomach muscles to
slow gastric emptying has been scarcely assessed. A study by Mulder
and colleagues [154] showed that amylin is able to relax gut muscle ex
vivo which may imply that amylin could inhibit gastric emptying
through this mechanism but whether this also takes place in vivo re-
mains to be determined.
6.2. Amylin's role in the glucose control
The prevalence of type 2 diabetes increases concomitantly with the
obesity epidemic and even though insulin therapies have improved,
many patients still experience difficulties in the management of their
glycemic control. Because under most circumstances, circulating
amylin and insulin levels change in parallel, the amylin analogue
pramlintide has been introduced as an adjunct therapy with insulin for
diabetes therapy to improve glucose control in type 1 and type 2 dia-
betes patients [155]. Indeed, pramlintide injection in addition to
mealtime insulin, delays gastric emptying and small intestin nutrient
absorption, slowing the appearance of meal-derived glucose into the
circulation and thus reducing postprandial glucose excursion in insulin
requiring diabetic patients [156,157]. Nevertheless, pramlintide cannot
reduce hyperglycemia following liquid glucose solution intake sug-
gesting that its effects on glycemia are mostly linked to the slowing of
gastric emptying [145,156,158].
Amylin has also been shown to act on pancreatic α-cells to inhibit
glucagon secretion [158]. Indeed, hepatic glucose production and gly-
cogenolysis are controlled by glucagon [159] and because type 1 and 2
diabetics fail to suppress postprandial glucagon secretion leading to
inappropriate hepatic glucose production and hyperglycemia
[160,161], amylin or its analog pramlintide reduce this maladaptation.
Similarly to pramlintide, dual AMY and CTR agonist (DACRA) have
been shown to exert positive effect on glucose metabolism in obese
rodents [162,163]. Amylin's effects on glucagon release was assessed
using hyperinsulinemic euglycemic clamp studies, and rats were ex-
posed to arginine, a well-known non-glucose secretagogue, followed by
hypoglycemia to stimulate glucagon secretion. Amylin was able to in-
hibit arginine-induced but not hypoglycemia-induced glucagon release
[80,164]. Since these effects require an intact animal and are not pre-
sent in isolated rodents islets [165], it implies that amylin action on
glucagon secretion is extrapancreatic and may be mediated by AP sig-
naling and the autonomic nervous system.
7. Conclusion
To conclude, amylin signals into multiple fore- and hindbrain areas
to perform a variety of physiological effects (Fig. 1). Amylin’s main
metabolic effects are triggered by the activation of AP neurons which
then propagate the signal to downstream nuclei. While AP neuronal
activation is well characterized, the actions mediated by its down-
stream nuclei, and whether forebrain and hindbrain signaling pathways
meet at the level of the LBPN remains to be clarified. Furthermore, this
review focused amylin brain circuitry in rodents, whether this is also
true in human needs to be assessed given the fact that human amylin
can form aggregates.
Nevertheless, given the number of physiological functions under
amylin control, the development of an amylin agonist could be a viable
pharmacological option to prevent obesity.
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